MR imaging and MR-guided biopsy of the prostate at 3T

Katarzyna Macura, Jurgen J. Fütterer

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Prostate cancer is a major public health and socioeconomic problem throughout the world. Prostate cancer is the most frequently diagnosed cancer in men. The 2009 report from the American Cancer Society projected 192 280 new cases of prostate cancer in the USA in 2009. With an estimated 27 360 deaths in the USA in 2009, prostate cancer is the second-leading cause of cancer death in men [1]. The high incidence of prostate cancer, combined with earlier detection and stage migration towards the smaller cancer volumes at the time of diagnosis, and the slow natural progression and heterogeneous biologic behavior of the disease make the management of prostate cancer a very complex and controversial issue. There is a wide discrepancy between the number of men diagnosed and those dying from prostate cancer. Incidence rates for prostate cancer have increased substantially over the past 20 years, in large part reflecting changes in prostate cancer screening with the prostate-specific antigen (PSA) blood test. In addition to PSA, screening for prostate cancer involves digital rectal examination (DRE) and transrectal ultrasonography (TRUS) with biopsy. Although elevated PSA levels can be suggestive of malignancy, benign conditions such as benign prostatic hyperplasia or prostatitis can also lead to PSA elevation [2]. It was demonstrated that only 25–40% of men with PSA above the 4 ng/ml threshold will be diagnosed with cancer, leading to about 60–75% of men in the PSA range 4–10 ng/ml undergoing an unnecessary biopsy [3]. In about 14% of men with prostate cancer, diagnosis can be established on the basis of DRE alone [4]. About 15% of men over the age of 60 have prostate cancer that is clinically silent, i.e., not detectable on DRE or with a PSA level of less than 4 ng/ml [5]. Thus, TRUS-guided core prostate biopsies are being used routinely to systematically sample the entire gland in patients with abnormal DRE and/or elevated PSA in the search for prostate cancer. Since prostate cancer is an age-related disease, the increasing life expectancy will result in further increase of both the incidence of and the deaths related to prostate cancer [6].

Original languageEnglish (US)
Title of host publicationBody MR Imaging at 3 Tesla
PublisherCambridge University Press
Pages178-196
Number of pages19
ISBN (Print)9780511978968, 9780521194860
DOIs
StatePublished - Jan 1 2011
Externally publishedYes

Fingerprint

Image-Guided Biopsy
Prostate
Prostatic Neoplasms
Prostate-Specific Antigen
Digital Rectal Examination
Neoplasms
Biopsy
Ultrasonography
Incidence
Prostatitis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Macura, K., & Fütterer, J. J. (2011). MR imaging and MR-guided biopsy of the prostate at 3T. In Body MR Imaging at 3 Tesla (pp. 178-196). Cambridge University Press. https://doi.org/10.1017/CBO9780511978968.015

MR imaging and MR-guided biopsy of the prostate at 3T. / Macura, Katarzyna; Fütterer, Jurgen J.

Body MR Imaging at 3 Tesla. Cambridge University Press, 2011. p. 178-196.

Research output: Chapter in Book/Report/Conference proceedingChapter

Macura, K & Fütterer, JJ 2011, MR imaging and MR-guided biopsy of the prostate at 3T. in Body MR Imaging at 3 Tesla. Cambridge University Press, pp. 178-196. https://doi.org/10.1017/CBO9780511978968.015
Macura K, Fütterer JJ. MR imaging and MR-guided biopsy of the prostate at 3T. In Body MR Imaging at 3 Tesla. Cambridge University Press. 2011. p. 178-196 https://doi.org/10.1017/CBO9780511978968.015
Macura, Katarzyna ; Fütterer, Jurgen J. / MR imaging and MR-guided biopsy of the prostate at 3T. Body MR Imaging at 3 Tesla. Cambridge University Press, 2011. pp. 178-196
@inbook{4fb343f1de1047d3a6327129840f52bf,
title = "MR imaging and MR-guided biopsy of the prostate at 3T",
abstract = "Prostate cancer is a major public health and socioeconomic problem throughout the world. Prostate cancer is the most frequently diagnosed cancer in men. The 2009 report from the American Cancer Society projected 192 280 new cases of prostate cancer in the USA in 2009. With an estimated 27 360 deaths in the USA in 2009, prostate cancer is the second-leading cause of cancer death in men [1]. The high incidence of prostate cancer, combined with earlier detection and stage migration towards the smaller cancer volumes at the time of diagnosis, and the slow natural progression and heterogeneous biologic behavior of the disease make the management of prostate cancer a very complex and controversial issue. There is a wide discrepancy between the number of men diagnosed and those dying from prostate cancer. Incidence rates for prostate cancer have increased substantially over the past 20 years, in large part reflecting changes in prostate cancer screening with the prostate-specific antigen (PSA) blood test. In addition to PSA, screening for prostate cancer involves digital rectal examination (DRE) and transrectal ultrasonography (TRUS) with biopsy. Although elevated PSA levels can be suggestive of malignancy, benign conditions such as benign prostatic hyperplasia or prostatitis can also lead to PSA elevation [2]. It was demonstrated that only 25–40{\%} of men with PSA above the 4 ng/ml threshold will be diagnosed with cancer, leading to about 60–75{\%} of men in the PSA range 4–10 ng/ml undergoing an unnecessary biopsy [3]. In about 14{\%} of men with prostate cancer, diagnosis can be established on the basis of DRE alone [4]. About 15{\%} of men over the age of 60 have prostate cancer that is clinically silent, i.e., not detectable on DRE or with a PSA level of less than 4 ng/ml [5]. Thus, TRUS-guided core prostate biopsies are being used routinely to systematically sample the entire gland in patients with abnormal DRE and/or elevated PSA in the search for prostate cancer. Since prostate cancer is an age-related disease, the increasing life expectancy will result in further increase of both the incidence of and the deaths related to prostate cancer [6].",
author = "Katarzyna Macura and F{\"u}tterer, {Jurgen J.}",
year = "2011",
month = "1",
day = "1",
doi = "10.1017/CBO9780511978968.015",
language = "English (US)",
isbn = "9780511978968",
pages = "178--196",
booktitle = "Body MR Imaging at 3 Tesla",
publisher = "Cambridge University Press",

}

TY - CHAP

T1 - MR imaging and MR-guided biopsy of the prostate at 3T

AU - Macura, Katarzyna

AU - Fütterer, Jurgen J.

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Prostate cancer is a major public health and socioeconomic problem throughout the world. Prostate cancer is the most frequently diagnosed cancer in men. The 2009 report from the American Cancer Society projected 192 280 new cases of prostate cancer in the USA in 2009. With an estimated 27 360 deaths in the USA in 2009, prostate cancer is the second-leading cause of cancer death in men [1]. The high incidence of prostate cancer, combined with earlier detection and stage migration towards the smaller cancer volumes at the time of diagnosis, and the slow natural progression and heterogeneous biologic behavior of the disease make the management of prostate cancer a very complex and controversial issue. There is a wide discrepancy between the number of men diagnosed and those dying from prostate cancer. Incidence rates for prostate cancer have increased substantially over the past 20 years, in large part reflecting changes in prostate cancer screening with the prostate-specific antigen (PSA) blood test. In addition to PSA, screening for prostate cancer involves digital rectal examination (DRE) and transrectal ultrasonography (TRUS) with biopsy. Although elevated PSA levels can be suggestive of malignancy, benign conditions such as benign prostatic hyperplasia or prostatitis can also lead to PSA elevation [2]. It was demonstrated that only 25–40% of men with PSA above the 4 ng/ml threshold will be diagnosed with cancer, leading to about 60–75% of men in the PSA range 4–10 ng/ml undergoing an unnecessary biopsy [3]. In about 14% of men with prostate cancer, diagnosis can be established on the basis of DRE alone [4]. About 15% of men over the age of 60 have prostate cancer that is clinically silent, i.e., not detectable on DRE or with a PSA level of less than 4 ng/ml [5]. Thus, TRUS-guided core prostate biopsies are being used routinely to systematically sample the entire gland in patients with abnormal DRE and/or elevated PSA in the search for prostate cancer. Since prostate cancer is an age-related disease, the increasing life expectancy will result in further increase of both the incidence of and the deaths related to prostate cancer [6].

AB - Prostate cancer is a major public health and socioeconomic problem throughout the world. Prostate cancer is the most frequently diagnosed cancer in men. The 2009 report from the American Cancer Society projected 192 280 new cases of prostate cancer in the USA in 2009. With an estimated 27 360 deaths in the USA in 2009, prostate cancer is the second-leading cause of cancer death in men [1]. The high incidence of prostate cancer, combined with earlier detection and stage migration towards the smaller cancer volumes at the time of diagnosis, and the slow natural progression and heterogeneous biologic behavior of the disease make the management of prostate cancer a very complex and controversial issue. There is a wide discrepancy between the number of men diagnosed and those dying from prostate cancer. Incidence rates for prostate cancer have increased substantially over the past 20 years, in large part reflecting changes in prostate cancer screening with the prostate-specific antigen (PSA) blood test. In addition to PSA, screening for prostate cancer involves digital rectal examination (DRE) and transrectal ultrasonography (TRUS) with biopsy. Although elevated PSA levels can be suggestive of malignancy, benign conditions such as benign prostatic hyperplasia or prostatitis can also lead to PSA elevation [2]. It was demonstrated that only 25–40% of men with PSA above the 4 ng/ml threshold will be diagnosed with cancer, leading to about 60–75% of men in the PSA range 4–10 ng/ml undergoing an unnecessary biopsy [3]. In about 14% of men with prostate cancer, diagnosis can be established on the basis of DRE alone [4]. About 15% of men over the age of 60 have prostate cancer that is clinically silent, i.e., not detectable on DRE or with a PSA level of less than 4 ng/ml [5]. Thus, TRUS-guided core prostate biopsies are being used routinely to systematically sample the entire gland in patients with abnormal DRE and/or elevated PSA in the search for prostate cancer. Since prostate cancer is an age-related disease, the increasing life expectancy will result in further increase of both the incidence of and the deaths related to prostate cancer [6].

UR - http://www.scopus.com/inward/record.url?scp=84926075403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926075403&partnerID=8YFLogxK

U2 - 10.1017/CBO9780511978968.015

DO - 10.1017/CBO9780511978968.015

M3 - Chapter

AN - SCOPUS:84926075403

SN - 9780511978968

SN - 9780521194860

SP - 178

EP - 196

BT - Body MR Imaging at 3 Tesla

PB - Cambridge University Press

ER -